Testicular cancer survival statistics

Coronavirus (COVID-19)

We have created a central resources hub for Health Professionals which hosts all of our CRUK resources and further materials to help with managing the pandemic. We are updating the information as guidance changes. There is also a page specifically for patients on our about cancer hub.

Health Professional COVID-19 and Cancer Hub

Survival

Survive testicular cancer for 10 or more years, 2013-2017, England and Wales

Age

Age that testicular cancer survival is highest, 2009-2013, England

 

Improvement

Testicular cancer survival in the UK has increased in the last 40 years

 

96.5% of males survive testicular cancer for at least one year, this remains similar at 95.3% surviving for five years or more, as shown by age-standardised net survival for patients diagnosed with testicular cancer during 2013-2017 in England.[1]

Testicular Cancer Age-Standardised One-, Five- and Ten-Year Net Survival, Adults (Aged 15-99), England, 2013-2017

The bar chart shows one- and five-year net survival and predicted ten-year net survival, with 95% confidence intervals. Open a glossary item
 

Testicular cancer survival falls only slightly beyond five years after diagnosis. 91.3% of males are predicted to survive their disease for ten years or more, as shown by age-standardised net survival for patients diagnosed with testicular cancer during 2013-2017 in England.[1]

References

  1. Office for National Statistics, Cancer survival by stage at diagnosis for England, 2019.

About this data

Data is for England, 2013 - 2017, ICD-10 C67.

Survival statistics give an overall picture of survival and the survival time experienced by an individual patient may be much higher or lower, depending on specific patient and tumour characteristics.

Last reviewed:

Five-year survival for testicular cancer is generally higher in younger men and decreases with increasing age. Five-year net survival ranges from 98% in 40-49 year-olds to 68% in 80-99 year-olds for patients diagnosed with testicular cancer in England during 2009-2013.[1]

Testicular Cancer (C62), Five-Year Net Survival by Age, Men, England, 2009-2013

Last reviewed:

As with most cancers, survival for testicular cancer is improving. One-year age-standardised Open a glossary item net survival has increased from 83% during 1971-1972 to 99% during 2010-2011 in England and Wales – an absolute survival difference Open a glossary item of 16 percentage points.[1]

Testicular Cancer (C62), Age-Standardised One-Year Net Survival, Men (Aged 15-99), England and Wales, 1971-2011

Five- and ten-year survival has increased by an even greater amount than one-year survival since the early 1970s. Five-year age-standardised net survival for testicular cancer has increased from 71% during 1971-1972 to a predicted survival of 98% during 2010-2011 in England and Wales – an absolute survival difference of 28 percentage points.[1]

Testicular Cancer (C62), Age-Standardised Five-Year Net Survival, Men (Aged 15-99), England and Wales, 1971-2011

Five-year survival for 2010-2011 is predicted using an excess hazard statistical model

Ten-year age-standardised net survival for testicular cancer has increased from 69% during 1971-1972 to a predicted survival of 98% during 2010-2011 in England and Wales – an absolute survival difference of 29 percentage points.[1] Overall, almost all men diagnosed with testicular cancer today are predicted to survive their disease for at least ten years.

Testicular Cancer (C62), Age-Standardised Ten-Year Net Survival, Men (Aged 15-99), England and Wales, 1971-2011

Ten-year survival for 2005-2006 and 2010-2011 is predicted using an excess hazard statistical model

References

  1. Data were provided by London School of Hygiene and Tropical  Medicine on request, 2014.

About this data

Data is for: England and Wales, 1971-2011, ICD-10 C62

Last reviewed:

Survival for testicular cancer is strongly related to stage of the disease at diagnosis.

One-year net survival by stage

One-year net survival for testicular cancer is highest for patients diagnosed at Stage 1, and lowest for those diagnosed at Stage 3, as 2013-2017 data for England show.[1] 99% of patients diagnosed at Stage 1 survived their disease for at least one year, compared to 86% of patients diagnosed at Stage 3.[1]

One year net survival for unknown or missing stage is 93%, while one year survival for unstageable cancer is 94%. Lack of staging information may in some cases reflect advanced stage at diagnosis as very unwell patients may not undergo staging tests if the invasiveness of the testing outweighs the potential benefit of obtaining stage information. Incomplete staging assessment may also be associated with socio-demographic and clinical characteristics of the patient [2]. Stage completeness for testicular cancer was 81% in 2013-2017 [1].

Net survival can be greater than 100% because it accounts for background mortality. Net survival greater than 100% indicates that patients in this group have a better chance of surviving one year after diagnosis compared with the general population.

Testicular cancer one-year net survival by stage, with incidence by stage (all data: adults diagnosed 2013-2017, followed up to 2018)

References

  1. Office for National Statistics, Cancer survival by stage at diagnosis for England, 2019.
  2. Girolamo, C. et al, Characteristics of patients with missing information on stage: a population-based study of patients diagnosed with a colon, lung or breast cancer in England in 2013, BMC Cancer (2018) 18:492

About this data

Data is for: England, 2013 - 2017, ICD-10 C62.

Survival statistics give an overall picture of survival but the survival time experienced by an individual patient may be much higher or lower, depending on specific patient and tumour characteristics.

Last reviewed:

Five-year relative survival for testicular cancer in men in England (92%) is above the average for Europe (89%). Wales (88%), Scotland (92%) and Northern Ireland (89%) are similar to the European average.[1] Across the European countries for which data is available, five-year relative survival in men ranges from 67% (Lithuania) to 95% (Sweden).[1]

Testicular Cancer (C62), Age-Standardised Five-Year Relative Survival, Males (Aged 15+), European Countries, 2000-2007

Data consists of both observed and predicted 5-year relative survival. Where sufficient follow-up was not available for recently diagnosed patients the period approach was used to predict 5-year cohort survival.

Possible explanations for persistent international differences in survival include differences in cancer biology, use of diagnostic tests and screening, stage at diagnosis, access to high-quality care, and data collection practices.[1]

References

  1. De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5 – a population-based study. Lancet Oncol 2014;15:23-34

About this data

Data is for: 29 European countries, patients diagnosed in 2000-2007 and followed up to 2008, testicular cancer (C62).

Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, 2 Redman Place, London, E20 1JQ or

Donate online

We’re now on twitter.
Join the conversation and follow @CRUKHCPs for news, updates and opinion.

@CRUKHCPs

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.